<SUBMISSION>
<ACCESSION-NUMBER>0000950134-07-006237
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>1
<PERIOD>20070316
<ITEMS>5.01
<ITEMS>5.02
<FILING-DATE>20070320
<DATE-OF-FILING-DATE-CHANGE>20070320
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADEZA BIOMEDICAL CORP
<CIK>0000902482
<ASSIGNED-SIC>3825
<IRS-NUMBER>770054952
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-20703
<FILM-NUMBER>07707023
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1240 ELKO DR
<CITY>SUNNYVALE
<STATE>CA
<ZIP>94089
</BUSINESS-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f28524e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Current Report<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported): March&nbsp;16, 2007</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Adeza Biomedical Corporation</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>000-20703</B><BR>
Commission File Number</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B><BR>
(State or other jurisdiction of <BR>
incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>77-0054952</B><BR>
(I.R.S. Employer Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>1240 Elko Drive<BR>
Sunnyvale, California 94089</B><BR>
(Address of principal executive offices, with zip code)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(408)&nbsp;745-0975</B><BR>
(Registrant&#146;s telephone number, including area code)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">(Former name or former address, if changed since last report)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below):
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link2 "Item&nbsp;5.01. Changes in Control of Registrant." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;5.01. Changes in Control of Registrant.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On February&nbsp;11, 2007, Adeza Biomedical Corporation (the &#147;Company&#148;) entered into an Agreement and
Plan of Merger (the &#147;Merger Agreement&#148;), with Cytyc Corporation, a Delaware corporation (&#147;Cytyc&#148;)
and Augusta Medical Corporation, a Delaware corporation and a direct wholly-owned subsidiary of
Cytyc (&#147;Purchaser&#148;), under which Purchaser has commenced a tender offer (the &#147;Offer&#148;) to purchase
all of the outstanding shares of the Company&#146;s common stock (the &#147;Shares&#148;) for a purchase price of
$24.00 per Share, net to the holders thereof, in cash (the &#147;Offer Price&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The initial offering period of the Offer expired on March&nbsp;16, 2007. On March&nbsp;19, 2007, Cytyc issued
a press release announcing the results of the Offer and that Purchaser had accepted for payment all
Shares tendered in the Offer through March&nbsp;16, 2007. Based on the number of Shares validly
tendered and accepted for payment at the end of the initial offering period of the Offer, Purchaser
has acquired 15,347,000 Shares, which represents approximately 87.4% of all outstanding Shares.
Based on the Offer Price, the value of such Shares purchased by Purchaser was approximately $368.3
million. Purchaser has acquired the funds used by Purchaser to purchase the Shares from Cytyc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cytyc also announced that Purchaser has commenced a subsequent offering period for all remaining
Shares to permit the Company stockholders who have not yet tendered their Shares the opportunity to
do so. This subsequent offering period will expire at 12:00 midnight, New York City time, on
Friday, March&nbsp;30, 2007, unless further extended. Any such extension will be followed by a public
announcement no later than 9:00 a.m., New York City time, on the next business day after the
subsequent offering period was scheduled to expire.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The same $24.00 per Share Offer Price will be paid during the subsequent offering period. All
Shares validly tendered during this subsequent offering period will be immediately accepted and
payment will be made promptly after acceptance, in accordance with the terms of the Offer.
Procedures for tendering Shares during the subsequent offering period are the same as during the
initial offering period with two exceptions: (1)&nbsp;Shares cannot be delivered by the guaranteed
delivery procedure, and (2)&nbsp;pursuant to Rule&nbsp;14d-7(a)(2) promulgated under the Securities Exchange
Act of 1934, as amended, Shares tendered during the subsequent offering period may not be
withdrawn.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the terms of the Merger Agreement, Cytyc expects to effect a merger of Purchaser with
and into the Company. In the merger, Purchaser will acquire all other Shares (other than those as
to which holders properly exercise appraisal rights) at the same $24.00 per Share price, without
interest and less any required withholding taxes, that was paid in the Offer. As a result of the
merger, the Company will become a wholly-owned subsidiary of Cytyc. Cytyc intends to complete the
merger as soon as practicable. If, as a result of additional Shares tendered and purchased in the
subsequent offering period or otherwise, Purchaser becomes the owner of at least 90% of the
outstanding Shares, Purchaser will be able to effect the merger without the need for a meeting of
the Company stockholders. The Company stockholders who continue to hold their Shares at the time of
the merger and fulfill certain other requirements of Delaware law will have appraisal rights in
connection with the merger.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Merger Agreement provides that, effective upon the acceptance for payment of the Shares
pursuant to the Offer, Purchaser will be entitled to elect or designate such number of directors
(the &#147;Purchaser Designees&#148;), rounded up to the next whole number, on the Company&#146;s board of
directors (the &#147;Board&#148;) as is equal to the product of (i)&nbsp;the total number of directors on the
Board (giving effect to the directors elected or designated by Purchaser pursuant to the Merger
Agreement) and (ii)&nbsp;the percentage that the aggregate number of Shares beneficially owned by Cytyc,
Purchaser and any of its affiliates bears to the total number of Shares then outstanding. The
Merger Agreement also provides that, not withstanding the foregoing, (i)&nbsp;in the event the Purchaser
Designees are elected to the Board, at least three directors who were directors of the Company on
February&nbsp;11, 2007, the date the Merger Agreement was signed, will continue to serve on the Board
until the effective time of the merger; (ii)&nbsp;each of such directors must be an &#147;independent
director&#148; as defined by Rule&nbsp;4200(a)(15) of the Nasdaq Stock Market Rules and eligible to serve on
the Company&#146;s audit committee under the Securities Exchange Act of 1934, as amended, and the Nasdaq
Stock Market Rules; and (iii)&nbsp;at least one such director must be an &#147;audit committee financial
expert&#148; as defined in Item 401(h) of Regulation&nbsp;S-K and the instructions thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">To the knowledge of the Company, except as set forth herein, there are no arrangements, including
any pledge by any person of securities of the Company, the operation of which may at a subsequent
date result in a change of control of the Company.
</DIV>
<!-- link2 "Item&nbsp;5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers; Compensatory Arrangements of Certain Officers.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The information contained in Item&nbsp;5.01 above is incorporated herein by reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the Merger Agreement as described in Item&nbsp;5.01 above and effective as of 2:00 p.m.
Eastern Time on March&nbsp;19, 2007, (i)&nbsp;Andrew E. Senyei, MD, who served as a member of the Board&#146;s
Compensation Committee; Emory V. Anderson; and Kathleen D. LaPorte, who served as a member of the
Board&#146;s Nominating and Corporate Governance Committee, each resigned as directors of the Company;
and (ii)&nbsp;the Board appointed Patrick J. Sullivan, John P. McDonough, Timothy M. Adams and Tony
Kingsley, each a Purchaser Designee, as a director to serve on the Board until his successor is
duly elected and qualified or until his earlier death, resignation or removal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The resignations of Dr.&nbsp;Senyei, Mr.&nbsp;Anderson and Ms.&nbsp;LaPorte were not the result of any
disagreement with the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Sullivan will serve as a class II director, Mr.&nbsp;McDonough will serve as a class I
director, Mr.&nbsp;Adams will serve as a class III director and Mr.&nbsp;Kingsley will serve as a class III
director. It has not yet been determined which committees of the Board to which these directors
are expected to be named.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following sets forth biographical information of the new directors:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Patrick J. Sullivan. </I>Mr.&nbsp;Sullivan has served as Cytyc&#146;s Chief Executive Officer and as one of
Cytyc&#146;s directors since March&nbsp;1994. In January&nbsp;2001, he was named Vice Chairman of the Board of
Directors and in January&nbsp;2002 he was named Chairman-elect. In May&nbsp;2002, Mr.&nbsp;Sullivan became
Chairman of the Board. From March&nbsp;1994 to January&nbsp;2002, and from July&nbsp;2002 to the present, Mr.
Sullivan also has been serving as President, and from January&nbsp;1991 to March&nbsp;1994, Mr.&nbsp;Sullivan
served as Vice President of Sales and Marketing. Prior to joining Cytyc, Mr.&nbsp;Sullivan was employed
in several senior marketing positions for five years by Abbott Laboratories, a diversified
healthcare company, and was a consultant with McKinsey and Company, an international management
consulting firm. Mr.&nbsp;Sullivan is a graduate, with distinction, of the United States Naval Academy
and received an M.B.A., with distinction, from Harvard University.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Timothy M. Adams. </I>Senior Vice President of Cytyc (since January&nbsp;2006). Concurrently serves as
Chief Financial Officer and Treasurer of Cytyc (since November&nbsp;2004). Vice President of Cytyc
(November&nbsp;2004 to January&nbsp;2006). Chief Financial Officer, Modus International, Inc. (October, 2002
to August, 2004). Chief Operating and Chief Financial Officer, GeoTrust (March to September&nbsp;2002).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Tony Kingsley. </I>President, Cytyc Diagnostic Products division and Senior Vice President of Cytyc
(since July&nbsp;2006). Partner and Associate with McKinsey &#038; Company, Inc. (November&nbsp;1991 to July
2006).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>John P. McDonough. </I>President, Cytyc Development Company LLC (since July&nbsp;2006). Concurrently serves
as Senior Vice President of Corporate Development of Cytyc. Senior Vice President of Operations of
Cytyc (March&nbsp;2004 to July&nbsp;2006). Vice President, Corporate Development of Cytyc (October&nbsp;2003 to
March&nbsp;2004). Founder, Chief Executive Officer and President of Soundbite Communications (April&nbsp;2000
to September&nbsp;2003).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">ADEZA BIOMEDICAL CORPORATION<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: March 20, 2007&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/
Mark D. Fischer-Colbrie
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark D. Fischer-Colbrie&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left"><I>Chief Financial Officer</I>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
